Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Graham

Showing results (1401-1410 of 1,460) with videos related to

Pageof 146
Sort By:
SSRN|August 4, 2020
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular ProbesTongqing Zhou, I-Ting Teng, Adam S Olia, et al.
Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.
Science Advances|March 20, 2021
Symptom clusters in COVID-19: A potential clinical prediction tool from the COVID Symptom Study appCarole H Sudre, Karla A Lee, Mary Ni Lochlainn, et al.
The New England Journal of Medicine|September 29, 2020
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsEvan J Anderson, Nadine G Rouphael, Alicia T Widge, et al.
The Lancet. HIV|September 2, 2019
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trialMartin R Gaudinski, Katherine V Houser, Nicole A Doria-Rose, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Annals of the New York Academy of Sciences|April 6, 2023
Progress in vaccine development for infectious diseases-a Keystone Symposia reportJennifer Cable, Barney S Graham, Richard A Koup, et al.
Immunity|April 6, 2021
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responsesMaryam Mukhamedova, Daniel Wrapp, Chen-Hsiang Shen, et al.
Scientific Data|February 6, 2025
WAND: A multi-modal dataset integrating advanced MRI, MEG, and TMS for multi-scale brain analysisCarolyn B McNabb, Ian D Driver, Vanessa Hyde, et al.
Pageof 146

Showing results (1401-1410 of 1,460) with videos related to

Sort By:
Pageof 146
SSRN|August 4, 2020
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular ProbesTongqing Zhou, I-Ting Teng, Adam S Olia, et al.
Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.
Science Advances|March 20, 2021
Symptom clusters in COVID-19: A potential clinical prediction tool from the COVID Symptom Study appCarole H Sudre, Karla A Lee, Mary Ni Lochlainn, et al.
The New England Journal of Medicine|September 29, 2020
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsEvan J Anderson, Nadine G Rouphael, Alicia T Widge, et al.
The Lancet. HIV|September 2, 2019
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trialMartin R Gaudinski, Katherine V Houser, Nicole A Doria-Rose, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Annals of the New York Academy of Sciences|April 6, 2023
Progress in vaccine development for infectious diseases-a Keystone Symposia reportJennifer Cable, Barney S Graham, Richard A Koup, et al.
Immunity|April 6, 2021
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responsesMaryam Mukhamedova, Daniel Wrapp, Chen-Hsiang Shen, et al.
Scientific Data|February 6, 2025
WAND: A multi-modal dataset integrating advanced MRI, MEG, and TMS for multi-scale brain analysisCarolyn B McNabb, Ian D Driver, Vanessa Hyde, et al.
Pageof 146